Literature DB >> 23691988

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.

Neil P Shah, Moshe Talpaz, Michael W N Deininger, Michael J Mauro, Ian W Flinn, Dale Bixby, Stephanie Lustgarten, Joseph M Gozgit, Tim Clackson, Christopher D Turner, Frank G Haluska, Hagop Kantarjian, Jorge E Cortes.   

Abstract

Entities:  

Keywords:  FLT3 internal tandem duplications; FMS-like tyrosine kinase-3; acute myeloid leukaemia; ponatinib; tyrosine kinase inhibitor

Mesh：

Substances：

Year:  2013        PMID： 23691988      PMCID： PMC3866040          DOI： 10.1111/bjh.12382

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

1.  Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.

Authors:  Catherine C Smith; Elisabeth A Lasater; Xiaotian Zhu; Kimberly C Lin; Whitney K Stewart; Lauren E Damon; Sara Salerno; Neil P Shah
Journal:  Blood       Date:  2013-02-21       Impact factor: 22.113

2.  Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.

Authors:  Joseph M Gozgit; Matthew J Wong; Scott Wardwell; Jeffrey W Tyner; Marc M Loriaux; Qurish K Mohemmad; Narayana I Narasimhan; William C Shakespeare; Frank Wang; Brian J Druker; Tim Clackson; Victor M Rivera
Journal:  Mol Cancer Ther       Date:  2011-04-11       Impact factor: 6.261

3.  Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Authors:  Catherine C Smith; Qi Wang; Chen-Shan Chin; Sara Salerno; Lauren E Damon; Mark J Levis; Alexander E Perl; Kevin J Travers; Susana Wang; Jeremy P Hunt; Patrick P Zarrinkar; Eric E Schadt; Andrew Kasarskis; John Kuriyan; Neil P Shah
Journal:  Nature       Date:  2012-04-15       Impact factor: 49.962

4.  Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.

Authors:  Gautam Borthakur; Hagop Kantarjian; Farhad Ravandi; Weiguo Zhang; Marina Konopleva; John J Wright; Stefan Faderl; Srdan Verstovsek; Sheela Mathews; Michael Andreeff; Jorge E Cortes
Journal:  Haematologica       Date:  2010-10-15       Impact factor: 9.941

Review 5.  The clinical development of FLT3 inhibitors in acute myeloid leukemia.

Authors:  Steven Knapper
Journal:  Expert Opin Investig Drugs       Date:  2011-09-06       Impact factor: 6.206

Review 6.  FLT3: ITDoes matter in leukemia.

Authors:  M Levis; D Small
Journal:  Leukemia       Date:  2003-09       Impact factor: 11.528

7.  Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Authors:  Jorge E Cortes; Hagop Kantarjian; Neil P Shah; Dale Bixby; Michael J Mauro; Ian Flinn; Thomas O'Hare; Simin Hu; Narayana I Narasimhan; Victor M Rivera; Tim Clackson; Christopher D Turner; Frank G Haluska; Brian J Druker; Michael W N Deininger; Moshe Talpaz
Journal:  N Engl J Med       Date:  2012-11-29       Impact factor: 91.245

8.  AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

Authors:  Thomas O'Hare; William C Shakespeare; Xiaotian Zhu; Christopher A Eide; Victor M Rivera; Frank Wang; Lauren T Adrian; Tianjun Zhou; Wei-Sheng Huang; Qihong Xu; Chester A Metcalf; Jeffrey W Tyner; Marc M Loriaux; Amie S Corbin; Scott Wardwell; Yaoyu Ning; Jeffrey A Keats; Yihan Wang; Raji Sundaramoorthi; Mathew Thomas; Dong Zhou; Joseph Snodgrass; Lois Commodore; Tomi K Sawyer; David C Dalgarno; Michael W N Deininger; Brian J Druker; Tim Clackson
Journal:  Cancer Cell       Date:  2009-11-06       Impact factor: 31.743
  8 in total
  29 in total

Review 1.  FLT3 inhibitors in AML: are we there yet?

Authors:  Akshay Sudhindra; Catherine Choy Smith
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

Review 2.  New drugs for acute myeloid leukemia inspired by genomics and when to use them.

Authors:  Daniel A Pollyea
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  Recent advances and novel agents for FLT3 mutated acute myeloid leukemia.

Authors:  Rahul Pawar; Omar Preet Singh Bali; Bharat Kumar Malhotra; Gurpreet Lamba
Journal:  Stem Cell Investig       Date:  2014-03-20

Review 4.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

Review 5.  Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?

Authors:  Keith W Pratz; Selina M Luger
Journal:  Curr Opin Hematol       Date:  2014-03       Impact factor: 3.284

6.  Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.

Authors:  Stephen E Kurtz; Christopher A Eide; Andy Kaempf; Vishesh Khanna; Samantha L Savage; Angela Rofelty; Isabel English; Hibery Ho; Ravi Pandya; William J Bolosky; Hoifung Poon; Michael W Deininger; Robert Collins; Ronan T Swords; Justin Watts; Daniel A Pollyea; Bruno C Medeiros; Elie Traer; Cristina E Tognon; Motomi Mori; Brian J Druker; Jeffrey W Tyner
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-07       Impact factor: 11.205

Review 7.  FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

Authors:  Mark Levis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

8.  Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors.

Authors:  Brendan Frett; Nick McConnell; Catherine C Smith; Yuanxiang Wang; Neil P Shah; Hong-yu Li
Journal:  Eur J Med Chem       Date:  2015-02-28       Impact factor: 6.514

Review 9.  Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.

Authors:  Naveen Pemmaraju; Hagop Kantarjian; Michael Andreeff; Jorge Cortes; Farhad Ravandi
Journal:  Expert Opin Investig Drugs       Date:  2014-04-21       Impact factor: 6.206

10.  BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.

Authors:  Warren Fiskus; Sunil Sharma; Jun Qi; Bhavin Shah; Santhana G T Devaraj; Christopher Leveque; Bryce P Portier; Swaminathan Iyer; James E Bradner; Kapil N Bhalla
Journal:  Mol Cancer Ther       Date:  2014-07-22       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.